North America Biopharmaceuticals Market Trends, Size, Segment and Growth by
Forecast to 2030

The North America biopharmaceuticals market was valued at US$ 151.22 billion in 2022
and is expected to reach US$ 315.74 billion by 2028. It is estimated to
register a CAGR of 13.1% from 2022 to 2028.

📚Download Full PDF Sample Copy of Market
Report @ https://www.businessmarketinsights.com/sample/BMIRE00028630

Potential to Treat Rare Diseases Drives North America Biopharmaceuticals Market

According to the National Institute of Health (NIH) report,
30 million Americans, accounting for 10% of the population, have one of the
~7,000 known rare diseases. Developing medicines for treating these rare
diseases presents both scientific and operational challenges. Complex biology
associated with rare diseases presents challenges for scientists to design and
implement new drug development programs. However, despite these
challenges, biopharmaceutical researchers in the North Americas have developed
new technologies for treating rare diseases and developing groundbreaking
therapies. Moreover, in the last decade, 350 orphan drugs have been approved by
USFDA, particularly for conditions lacking treatment or having limited
treatment options. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a
life-threatening, progressive cardiovascular rare disease characterized by the
abnormal functioning of the heart, causing infiltrative cardiomyopathy. Once
diagnosed, the median life expectancy is only ~2.5-3.5 years if left untreated.
Further, biopharmaceuticals company Ultragenyx Pharmaceutical Inc. is engaged
in the safety testing and dosage determination of molecules developed to treat
Glycogen Storage Disease (GSD) type 3, a serious rare and ultra-genetic
disease. The company initiated the clinical studies of UX053 in December 2021
to launch it as the first potential medicine for treating patients living with
GSD3. The UX053 mRNA can deliver large genes to targeted cells for achieving a
high uniformity of protein expression. The company plans to individualize mRNA
therapies based on the needs of each patient through the adjustment of dose
levels and frequency. Such clinical developments, launches, and approvals are
accelerating the North America biopharmaceuticals market expansion.

North America Biopharmaceuticals Market Overview

The North America biopharmaceuticals market is segmented
into the US, Canada, and Mexico. The market growth in this region is attributed
to the increasing incidence of cancer, growing product introduction in the
region, and technological advancements in biopharmaceuticals. The
biopharmaceuticals industry is at a pivotal stage in medical research with
tremendous potential to further revolutionize the treatment of costly and
debilitating diseases such as Alzheimer's, cancer, heart disease, and hepatitis
C. The rising burden of chronic diseases and increased investment in research
and development activities in the US are driving the market in the region. The
biopharmaceuticals industry makes important contributions to the US economy.
The US leads the world in most R&D investment and innovation indices. As of
2020, biopharmaceutical companies in the United States have more than 3,400
drugs in clinical development, accounting for almost half of the estimated
8,000 drugs worldwide (of which 1,100 are being developed to treat various
types of cancer). The biopharmaceuticals industry makes important contributions
to the US economy by creating direct economic activities and supporting
indirect activities. Pharmaceutical and medical manufacturing accounted for
0.95% of private sector value added in 2018. Biotech R&D facilities
accounted for another 0.23%. Data from the Centers for Disease Control and
Prevention (CDC), updated in July 2022, shows that coronary artery disease is
the most common form of heart disease. Approximately 20.1 million adults aged
20 and older in the United States suffer from this condition. According to CDC
data, someone suffers a heart attack every 40 seconds, and nearly 805,000
people in the US suffer a heart attack annually. All these factors are expected
to boost the North America biopharmaceuticals market growth significantly
during the forecast period.

North America Biopharmaceuticals Strategic Insights

Strategic insights for the North America Biopharmaceuticals
provides data-driven analysis of the industry landscape, including current
trends, key players, and regional nuances. These insights offer actionable
recommendations, enabling readers to differentiate themselves from competitors
by identifying untapped segments or developing unique value propositions.
Leveraging data analytics, these insights help industry players anticipate the
market shifts, whether investors, manufacturers, or other stakeholders. A
future-oriented perspective is essential, helping stakeholders anticipate
market shifts and position themselves for long-term success in this dynamic
region. Ultimately, effective strategic insights empower readers to make
informed decisions that drive profitability and achieve their business
objectives within the market.

Market leaders and key company profiles

  AbbVie Inc

  AGC Biologics AS

  Amgen Inc

  Boehringer
Ingelheim International GmbH

  Bristol-Myers
Squibb Co

  Eli Lilly and Co

  Johnson &
Johnson

  Lonza Group AG

  Thermo Fisher
Scientific Inc

  WuXi Biologics Inc



North America Biopharmaceuticals Regional Insights

The geographic scope of the North America Biopharmaceuticals
refers to the specific areas in which a business operates and competes.
Understanding local distinctions, such as diverse consumer preferences (e.g.,
demand for specific plug types or battery backup durations), varying economic
conditions, and regulatory environments, is crucial for tailoring strategies to
specific markets. Businesses can expand their reach by identifying underserved
areas or adapting their offerings to meet local demands. A clear market focus
allows for more effective resource allocation, targeted marketing campaigns,
and better positioning against local competitors, ultimately driving growth in
those targeted areas.

North America Biopharmaceuticals Market Segmentation

The North America biopharmaceuticals market is
segmented into product type, application, and country.

Based on product type, the North
America biopharmaceuticals market is segmented into monoclonal antibodies,
recombinant vaccines, conventional vaccines, recombinant growth factors,
purified proteins, recombinant proteins, recombinant hormones, recombinant
enzymes, cell & gene therapies, cytokines/interferon/interleukins, and
others. In 2022, the monoclonal antibodies segment held the largest share of
the North America biopharmaceuticals market.

The recombinant vaccines segment is further segmented into cancer vaccine,
malaria vaccine, Ebola vaccine, hepatitis-B vaccine, tetanus vaccine,
diphtheria vaccine, cholera vaccine, and others. The conventional vaccines
segment is further segmented into polio vaccine, pox vaccine, and others. The
recombinant growth factors segment is further segmented into erythropoietin and
granulocyte colony stimulating factor. The purified proteins segment is further
segmented into leukemia inhibitory factor (LIF), P53 protein, P38 protein, and
others. The recombinant proteins segment is further segmented into serum
albumin, amyloid protein, defensin, and transferrin. The recombinant hormones
segment is further segmented into recombinant human growth hormones,
recombinant insulin, and other recombinant hormones. The recombinant enzymes
segment is further segmented into enterokinase, cyclase, caspase, and
cathepsin. The cell & gene therapies segment is further segmented into
allogenic products, autologous products, and acellular products.

Based on application, the North America biopharmaceuticals market is segmented
into oncology, inflammatory & infectious disease, autoimmune disorders,
metabolic disorders, hormonal disorders & growth failure, cardiovascular
diseases, neurological diseases, and others. In 2022, the oncology segment held
the largest share of the North America biopharmaceuticals market.

Based on country, the North America biopharmaceuticals market is segmented into
the US, Canada, and Mexico. In 2022, the US accounted for the largest share of
the North America biopharmaceuticals market.

AbbVie Inc, AGC Biologics AS, Amgen Inc, Boehringer Ingelheim International
GmbH, Bristol-Myers Squibb Co, Eli Lilly and Co, Johnson & Johnson, Lonza
Group AG, Thermo Fisher Scientific Inc, and WuXi Biologics Inc are the leading
companies operating in the North America biopharmaceuticals market.

Can you see this our reports

Europe Learning Management System Market – https://postyourarticle.com/europe-learning-management-system-market-trends-size-segment-and-growth-by-forecast-to-2030-4/

Europe Dental Market – https://github.com/businessmarketinsights985/business-market-insights/issues/18

North America Medical Laser Systems Market

– https://findit.com/uwttwdjttmkjdpa/RightNow/northamerica-medical-laser-systemss/ea672c78-2f49-4851-986c-6f17f7e783af


Europe Railway Cyber Security Market – https://businessmarketins02.blogspot.com/2025/05/europe-railway-cyber-security-market.html


Europe Antibiotics Market – https://sites.google.com/view/businessmarketinsights126/home


About Us:

Business Market Insights is a market research platform that provides
subscription service for industry and company reports. Our research team has
extensive professional expertise in domains such as Electronics &
Semiconductor; Aerospace & Défense; Automotive & Transportation; Energy
& Power; Healthcare; Manufacturing & Construction; Food &
Beverages; Chemicals & Materials; and Technology, Media, &
Telecommunications

Author’s Bio
Akshay
Senior Market Research Expert at Business Market Insights